Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
1.25
+0.05 (4.17%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.19 - 1.25
52 week 1.07 - 5.19
Open 1.20
Vol / Avg. 1.66M/2.19M
Mkt cap 191.30M
P/E     -
Div/yield     -
EPS -0.07
Shares 153.04M
Beta 2.27
Inst. own 68%
Mar 3, 2015
Q4 2014 Zogenix Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Zogenix, Inc. at Oppenheimer Healthcare Conference - Webcast
Nov 18, 2014
Zogenix, Inc. at Stifel Healthcare Conference
Nov 6, 2014
Q3 2014 Zogenix Inc Earnings Call - Webcast
Nov 6, 2014
Q3 2014 Zogenix Inc Earnings Release
Oct 27, 2014
Zogenix Acquires U.K.-Based Brabant Pharma Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -145.79% -244.93%
Operating margin -234.91% -161.13%
EBITD margin - -153.00%
Return on average assets -42.81% -83.71%
Return on average equity -81.75% -491.54%
Employees 114 -
CDP Score - -

Address

12400 High Bluff Dr Ste 650
SAN DIEGO, CA 92130-3006
United States - Map
+1-858-2591165 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In April 2014, Endo International PLC acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Director
Age: 55
Bio & Compensation  - Reuters
Roger L. Hawley Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
R. Scott Shively Executive Vice President, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 49
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 51
Bio & Compensation  - Reuters
Mark C. Wiggins Independent Director
Age: 58
Bio & Compensation  - Reuters